Removal of nuclear fission reactors: Our medical isotope production process relies on accelerator-driven technology for Mo-99 production instead of a nuclear fission reactor (as has been commonplace in the diagnostic radiopharmaceuticals industry), using our fusion neutron generator as the driver. Our process removes the need for a nuclear reactor. Utilizing our deuterium-tritium fusion-based neutron source reduces the nuclear waste associated with current Mo-99 production techniques.
Removal of highly enriched uranium: Highly enriched uranium, or HEU, has the risk of possibly being diverted from use in energy production to use in nuclear weapons production. Instead of using solid HEU, our target solution is a liquid-based low enriched uranium, or LEU, that is produced by converting HEU to LEU.
Reusable target liquid: Our liquid LEU target solution can be recycled into our production system after each use. This recyclable target solution further reduces nuclear waste production and increases the ease of separation.
Commercially viable Mo-99 produced: Our production process results in Mo-99 that is of high quality and high purity, resulting in Mo-99 that has high specific activity and is ready for delivery to our medical customers for use in modern nuclear medicine.